Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EPS (Basic) (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed EPS (Basic) for 14 consecutive years, with -$0.11 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 120.0% year-over-year to -$0.11, compared with a TTM value of -$0.35 through Dec 2025, down 9.38%, and an annual FY2025 reading of -$0.39, up 7.14% over the prior year.
  • EPS (Basic) was -$0.11 for Q4 2025 at Abvc Biopharma, down from -$0.05 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.26 in Q4 2023 and bottomed at -$4.82 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.58, with a median of -$0.12 recorded in 2025.
  • The sharpest move saw EPS (Basic) tumbled 2962.5% in 2022, then surged 112.2% in 2024.
  • Year by year, EPS (Basic) stood at -$0.31 in 2021, then crashed by 1454.84% to -$4.82 in 2022, then soared by 105.39% to $0.26 in 2023, then crashed by 119.23% to -$0.05 in 2024, then crashed by 120.0% to -$0.11 in 2025.
  • Business Quant data shows EPS (Basic) for ABVC at -$0.11 in Q4 2025, -$0.05 in Q3 2025, and -$0.13 in Q2 2025.